<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PLAVIX- clopidogrel bisulfate tablet, film coated </strong><br>Bryant Ranch Prepack<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
HIGHLIGHTS OF PRESCRIBING INFORMATION <br>
These highlights do not include all the information needed to use <br>
PLAVIX safely and effectively. See full prescribing information for <br>
PLAVIX. <br><br>
PLAVIX (clopidogrel bisulfate) tablets <br>
Initial U.S. Approval: 1997</div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING:  DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (<a href="#S12.5">12.5</a>)</span></li>
<li><span class="Bold">Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (<a href="#S12.5">12.5</a>)</span></li>
<li><span class="Bold">Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (<a href="#S2.3">2.3</a>, <a href="#S5.1">5.1</a>)</span></li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="65%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Dosage and Administration (<a href="#S2.3">2.3</a>, <a href="#S2.4">2.4</a>)</td>
<td align="left">08/2010</td>
</tr>
<tr class="Botrule Last">
<td align="left">Warnings and Precautions (<a href="#S5.1">5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>)</td>
<td align="left">08/2010</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING:  DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (<a href="#S12.5">12.5</a>)</span></li>
<li><span class="Bold">Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (<a href="#S12.5">12.5</a>)</span></li>
<li><span class="Bold">Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (<a href="#S2.3">2.3</a>, <a href="#S5.1">5.1</a>)</span></li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Plavix is a P2Y<span class="Sub">12</span> platelet inhibitor indicated for: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute coronary syndrome</span> <dl>
<dt>-</dt>
<dd> For patients with non-ST-segment elevation ACS [<span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> (UA)/non-ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> as well as the rate of a combined endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. (<a href="#S1.1">1.1</a>)</dd>
<dt>-</dt>
<dd> For patients with ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>), Plavix has been shown to reduce the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause and the rate of a combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The benefit for patients who undergo primary PCI is unknown. (<a href="#S1.1">1.1</a>)</dd>
</dl>
</li>
<li>Recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (fatal or not), new MI (fatal or not), and other vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. (<a href="#S1.2">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute coronary syndrome</span> (<a href="#S2.1">2.1</a>)<dl>
<dt>-</dt>
<dd> Non-ST-segment elevation ACS (UA/NSTEMI): 300 mg loading dose followed by 75 mg once daily, in combination with aspirin (75–325 mg once daily)</dd>
<dt>-</dt>
<dd> <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>:  75 mg once daily, in combination with aspirin (75–325 mg once daily), with or without a loading dose and with or without thrombolytics</dd>
</dl>
</li>
<li>Recent MI, recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or established peripheral arterial disease: 75 mg once daily (<a href="#S2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 75 mg, 300 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, such as <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> (<a href="#S4.1">4.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to clopidogrel or any component of the product (<a href="#S4.2">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with drugs that are strong or moderate CYP2C19 inhibitors (e.g., omeprazole). (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: Plavix increases risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Discontinue 5 days prior to elective surgery. (<a href="#S5.2">5.2</a>)</li>
<li>Discontinuation of Plavix: Premature discontinuation increases risk of cardiovascular events. (<a href="#S5.3">5.3</a>)</li>
<li>Recent transient ischemic attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: Combination use of Plavix and aspirin in these patients was not shown to be more effective than Plavix alone, but was shown to increase major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> (TTP): TTP has been reported with Plavix, including fatal cases. (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, including life-threatening and fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, is the most commonly reported adverse reaction. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Nonsteroidal anti-inflammatory drugs (NSAIDs): Combination use increases risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. (<a href="#S7.2">7.2</a>)</li>
<li>Warfarin: Combination use increases risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing mothers: Discontinue drug or nursing, taking into consideration importance of drug to mother. (<a href="#S8.3">8.3</a>)  </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</a></h1>
<h2><a href="#section-1.1" class="toc"></a></h2>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span> (ACS)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Recent MI, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	<span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2   Recent MI, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   CYP2C19 Poor Metabolizers</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Use with Proton Pump Inhibitors (PPI) </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	  General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Discontinuation of Plavix</a></h2>
<h2><a href="#section-5.4" class="toc">5.4   Patients with Recent Transient Ischemic Attack (TIA) or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5   <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span> (TTP)</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1   Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2   Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1   CYP2C19 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2   Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3   Warfarin (CYP2C9 Substrates) </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.5   Pharmacogenomics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14   CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1   <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span> </a></h2>
<h2><a href="#section-13.2" class="toc">14.2   Recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Lack of Established Benefit of Plavix plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1	Benefits and Risks</a></h2>
<h2><a href="#section-14.2" class="toc">17.2	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-14.3" class="toc">17.3	Other Signs and Symptoms Requiring Medical Attention</a></h2>
<h2><a href="#section-14.4" class="toc">17.4	Invasive Procedures</a></h2>
<h2><a href="#section-14.5" class="toc">17.5	Concomitant Medications</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING:  DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">The effectiveness of Plavix is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.  Plavix at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.  Poor metabolizers with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> or undergoing percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.  Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>.  Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span> (ACS)</h2>
<ul>
<li>For patients with non-ST-segment elevation ACS [<span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> (UA)/non-ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> as well as the rate of a combined endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or refractory <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.</li>
<li>For patients with ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>), Plavix has been shown to reduce the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause and the rate of a combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.</li>
</ul>
<p class="First">The optimal duration of Plavix therapy in ACS is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Recent MI, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</h2>
<p class="First">For patients with a history of recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (fatal or not), new MI (fatal or not), and other vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	<span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span></h2>
<p class="First">Plavix can be administered with or without food <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
<ul>
<li>For patients with non-ST-elevation ACS (UA/NSTEMI), initiate Plavix with a single 300 mg oral loading dose and then continue at 75 mg once daily.  Initiate aspirin (75–325 mg once daily) and continue in combination with Plavix <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</li>
<li>For patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>, the recommended dose of Plavix is 75 mg once daily orally, administered in combination with aspirin (75–325 mg once daily), with or without thrombolytics. Plavix may be initiated with or without a loading dose <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2   Recent MI, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</h2>
<p class="First">The recommended daily dose of Plavix is 75 mg once daily orally, with or without food <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3   CYP2C19 Poor Metabolizers</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel.  Although a higher dose regimen in poor metabolizers increases antiplatelet response <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>, an appropriate dose regimen for this patient population has not been established.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Use with Proton Pump Inhibitors (PPI) </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Omeprazole, a moderate CYP2C19 inhibitor, reduces the pharmacological activity of Plavix. Avoid using omeprazole concomitantly or 12 hours apart with Plavix. Consider using another acid-reducing agent with less CYP2C19 inhibitory activity. A higher dose regimen of clopidogrel concomitantly administered with omeprazole increases antiplatelet response; an appropriate dose regimen has not been established <span class="Italics">[see <a href="#S5.1">Warnings and Precautions  (5.1)</a>, <a href="#S7.1">Drug Interactions (7.1)</a> and <a href="#S12.5">Clinical Pharmacology (12.5)</a>].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other </li>
<li>300 mg tablets: Pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Plavix is contraindicated in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> such as <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </h2>
<p class="First">Plavix is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to clopidogrel or any component of the product <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 <span class="Italics">[see <a href="#box">Boxed Warning</a>]</span> and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of Plavix and strong or moderate CYP2C19 inhibitors.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Omeprazole, a moderate CYP2C19 inhibitor, has been shown to reduce the pharmacological activity of Plavix if given concomitantly or if given 12 hours apart. Consider using another acid-reducing agent with less CYP2C19 inhibitory activity. Pantoprazole, a weak CYP2C19 inhibitor, had less effect on the pharmacological activity of Plavix than omeprazole  <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a> and <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	  General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Thienopyridines, including Plavix, increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If a patient is to undergo surgery and an antiplatelet effect is not desired, discontinue Plavix five days prior to surgery. In patients who stopped therapy more than five days prior to CABG the rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were similar (event rate 4.4% Plavix + aspirin; 5.3% placebo + aspirin).  In patients who remained on therapy within five days of CABG, the major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate was 9.6% for Plavix + aspirin, and 6.3% for placebo + aspirin.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7–10 days), so withholding a dose will not be useful in managing a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event or the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with an invasive procedure.  Because the half-life of clopidogrel's active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Discontinuation of Plavix</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Avoid lapses in therapy, and if Plavix must be temporarily discontinued, restart as soon as possible.  Premature discontinuation of Plavix may increase the risk of cardiovascular events.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4   Patients with Recent Transient Ischemic Attack (TIA) or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></h2>
<p class="First">In patients with recent TIA or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> who are at high risk for recurrent ischemic events, the combination of aspirin and Plavix has not been shown to be more effective than Plavix alone, but the combination has been shown to increase major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5   <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span> (TTP)</h2>
<p class="First">TTP, sometimes fatal, has been reported following use of Plavix, sometimes after a short exposure (&lt;2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span> (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed below and elsewhere in the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1   Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions and durations of follow up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for 1 year or more.  The clinically important adverse reactions observed in trials comparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirin alone are discussed below. </p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p><span class="Italics">CURE</span></p>
<p>In CURE, Plavix use with aspirin was associated with an increase in major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (primarily gastrointestinal and at puncture sites) compared to placebo with aspirin (see <a href="#Table_1">Table 1</a>).  The incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> (0.1%) and fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (0.2%) were the same in both groups. Other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events that were reported more frequently in the clopidogrel group were <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span>.</p>
<p>The overall incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is described in Table 1. </p>
<a name="table_1"></a><table width="100%">
<caption><span>Table 1:  CURE Incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Complications (% patients)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th align="left">Event</th>
<th align="center">Plavix<br> (+ aspirin)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th align="center">Placebo<br> (+ aspirin)<a href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center">(n=6259)</th>
<th align="center">(n=6303)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Other standard therapies were used as appropriate.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Life-threatening and other major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rate for Plavix + aspirin was dose-dependent on aspirin: &lt;100 mg = 2.6%; 100–200 mg = 3.5%; &gt;200 mg = 4.9%<br>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rates for Plavix + aspirin by age were: &lt;65 years = 2.5%, ≥65 to &lt;75 years = 4.1%, ≥75 years = 5.9%</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rate for placebo + aspirin was dose-dependent on aspirin: &lt;100 mg = 2.0%; 100–200 mg = 2.3%; &gt;200 mg = 4.0%<br>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rates for placebo + aspirin by age were: &lt;65 years = 2.1%, ≥65 to &lt;75 years = 3.1%, ≥75 years = 3.6%</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Led to interruption of study medication.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">3.7 <a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td align="center">2.7 <a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
</tr>
<tr>
<td align="left">  Life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="center">2.2</td>
<td align="center">1.8</td>
</tr>
<tr>
<td align="left">    Fatal</td>
<td align="center">0.2</td>
<td align="center">0.2</td>
</tr>
<tr>
<td align="left">    5 g/dL hemoglobin drop</td>
<td align="center">0.9</td>
<td align="center">0.9</td>
</tr>
<tr>
<td align="left">    Requiring <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span></td>
<td align="center">0.7</td>
<td align="center">0.7</td>
</tr>
<tr>
<td align="left">    <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic strokes</span></td>
<td align="center">0.1</td>
<td align="center">0.1</td>
</tr>
<tr>
<td align="left">    Requiring inotropes</td>
<td align="center">0.5</td>
<td align="center">0.5</td>
</tr>
<tr>
<td align="left">    Requiring transfusion (≥4 units)</td>
<td align="center">1.2</td>
<td align="center">1.0</td>
</tr>
<tr>
<td align="left">Other major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="center">1.6</td>
<td align="center">1.0</td>
</tr>
<tr>
<td align="left">    Significantly disabling</td>
<td align="center">0.4</td>
<td align="center">0.3</td>
</tr>
<tr>
<td align="left">    Intraocular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with significant <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span></td>
<td align="center">0.05</td>
<td align="center">0.03</td>
</tr>
<tr>
<td align="left">    Requiring 2–3 units of blood</td>
<td align="center">1.3</td>
<td align="center">0.9</td>
</tr>
<tr class="Last">
<td align="left">Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td align="center">5.1</td>
<td align="center">2.4</td>
</tr>
</tbody>
</table>
<p>Ninety-two percent (92%) of the patients in the CURE study received heparin or low molecular weight heparin (LMWH), and the rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in these patients was similar to the overall results.</p>
<p><span class="Italics">COMMIT</span></p>
<p>In COMMIT, similar rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were observed in the Plavix and placebo groups, both of which also received aspirin (see <a href="#Table_2">Table 2</a>). </p>
<a name="table_2"></a><table width="100%">
<caption><span>Table 2: Incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events in COMMIT (% patients)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></th>
<th class="Rrule" align="center">Plavix<br>(+ aspirin)<br>(n=22961)</th>
<th class="Rrule" align="center">Placebo<br>(+ aspirin)<br>(n=22891)</th>
<th class="Rrule" align="center">p-value</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Major bleeds were cerebral bleeds or non-cerebral bleeds thought to have caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or that required transfusion.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>The relative rate of major noncerebral or cerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was independent of age. Event rates for Plavix + aspirin by age were: &lt;60 years = 0.3%, ≥60 to &lt;70 years = 0.7%, ≥70 years = 0.8%. Event rates for placebo + aspirin by age were: &lt;60 years = 0.4%, ≥60 to &lt;70 years = 0.6%, ≥70 years = 0.7%.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Major<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> noncerebral or cerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">0.5</td>
<td class="Rrule" align="center">0.59</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Major noncerebral</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center">0.48</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">    Fatal</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.90</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">Hemorrhagic stroke</span> </td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.91</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Fatal</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.81</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Other noncerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (non-major)</td>
<td class="Rrule" align="center">3.6</td>
<td class="Rrule" align="center">3.1</td>
<td class="Rrule" align="center">0.005</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Any noncerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Rrule" align="center">3.9</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">0.004</td>
</tr>
</tbody>
</table>
<p><span class="Italics">CAPRIE (Plavix vs. Aspirin)</span></p>
<p>In CAPRIE, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> occurred at a rate of 2.0% in those taking Plavix vs. 2.7% in those taking aspirin; <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring hospitalization occurred in 0.7% and 1.1%, respectively.  The incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> was 0.4% for Plavix compared to 0.5% for aspirin.</p>
<p>Other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events that were reported more frequently in the Plavix group were <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>.</p>
<p><span class="Italics Underline">Other Adverse Events</span></p>
<p>In CURE and CHARISMA, which compared Plavix plus aspirin to aspirin alone, there was no difference in the rate of adverse events (other than <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) between Plavix and placebo.</p>
<p>In CAPRIE, which compared Plavix to aspirin, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> was more frequently reported in those taking Plavix. No other difference in the rate of adverse events (other than <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) was reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2   Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Plavix. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<ul>
<li>
<span class="Italics">Blood and lymphatic system disorders</span>: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>/<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (TTP)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span>:  Eye (conjunctival, ocular, retinal) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> Gastrointestinal and <span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">retroperitoneal hemorrhage</span> with fatal outcome, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including ulcerative or <span class="product-label-link" type="condition" conceptid="4151446" conceptname="Lymphocytic-plasmacytic colitis">lymphocytic colitis</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, gastric/<span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>
<span class="Italics">General disorders and administration site condition</span>:  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> of operative <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span></li>
<li>
<span class="Italics">Hepato-biliary disorders:</span> <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">Acute liver failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (non-infectious), abnormal liver function test</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span></li>
<li>
<span class="Italics">Musculoskeletal, connective tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorders</span>:</span>  Musculoskeletal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>:  Taste disorders, fatal intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>
<span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> </li>
<li>
<span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, respiratory tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>
<span class="Italics">Renal and urinary disorders:</span> Increased creatinine levels</li>
<li>
<span class="Italics">Skin and subcutaneous tissue disorders:</span>  Maculopapular or erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, skin <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span></li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1   CYP2C19 Inhibitors</h2>
<p class="First">Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1) </a>and <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</p>
<p><span class="Italics Underline">Proton Pump Inhibitors (PPI)</span></p>
<p>A study was conducted with Plavix (300 mg loading dose followed by 75 mg/day) administered with a high dose (80 mg/day) of omeprazole. As shown in Table 3 below, with concomitant dosing of omeprazole, exposure (Cmax and AUC) to the clopidogrel active metabolite and platelet inhibition were substantially reduced. Similar reductions in exposure to the clopidogrel active metabolite and platelet inhibition were observed when Plavix and omeprazole were administered 12 hours apart (data not shown). </p>
<p>There are no adequate studies of a lower dose of omeprazole or a higher dose of Plavix in comparison with the approved dose of Plavix.</p>
<p>A study was conducted using Plavix (300 mg loading dose followed by 75 mg/day) and a high dose (80 mg/day) of pantoprazole, a PPI with less CYP2C19 inhibitory activity than omeprazole. The plasma concentrations of the clopidogrel active metabolite and the degree of platelet inhibition were less than observed with Plavix alone but were greater than observed when omeprazole 80 mg was co-administered with 300 mg loading dose followed by 75 mg/day of Plavix (Table 3). </p>
<table width="85%">
<caption><span>Table 3. Comparison of Clopidogrel Active Metabolite Exposure and Platelet Inhibition with and without Proton Pump Inhibitors, Omeprazole and Pantoprazole</span></caption>
<col align="center" valign="bottom" width="28">
<col align="center" valign="bottom" width="12">
<col align="center" valign="bottom" width="12">
<col align="center" valign="bottom" width="12">
<col align="center" valign="bottom" width="12">
<col align="center" valign="bottom" width="12">
<col align="center" valign="bottom" width="12">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="center"> </th>
<th class="Lrule Rrule" align="center" colspan="6"></th>
</tr>
<tr>
<th class="Lrule" align="center"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="6">% Change from Plavix (300 mg/75 mg) alone</th>
</tr>
<tr class="Botrule">
<th class="Lrule" align="center">Plavix plus</th>
<th class="Lrule" align="center" colspan="2">C<span class="Sub">max</span> (ng/mL)</th>
<th class="Lrule" align="center" colspan="2">AUC</th>
<th class="Lrule Rrule" align="center" colspan="2">Platelet Inhibition<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> (%)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center">Day 1</th>
<th class="Lrule" align="center">Day 5</th>
<th class="Lrule" align="center">Day 1</th>
<th class="Lrule Rrule" align="center">Day 5<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</th>
<th class="Lrule" align="center">Day 1</th>
<th class="Lrule Rrule" align="center">Day 5</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Inhibition of platelet aggregation with 5 mcM ADP</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>AUC at Day 5 is AUC<span class="Sub">0–24</span>
</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Similar results seen when Plavix and omeprazole were administered 12 hours apart.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">Omeprazole<a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a> 80 mg</td>
<td class="Lrule" align="center">↓46%</td>
<td class="Lrule" align="center">↓42%</td>
<td class="Lrule" align="center">↓45%</td>
<td class="Lrule" align="center">↓40%</td>
<td class="Lrule" align="center">↓39%</td>
<td class="Lrule Rrule" align="center">↓21%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">Pantoprazole 80 mg</td>
<td class="Lrule" align="center">↓24%</td>
<td class="Lrule" align="center">↓28%</td>
<td class="Lrule" align="center">↓20%</td>
<td class="Lrule" align="center">↓14%</td>
<td class="Lrule" align="center">↓15%</td>
<td class="Lrule Rrule" align="center">↓11%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2   Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class="First">Coadministration of Plavix and NSAIDs increases the risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3   Warfarin (CYP2C9 Substrates) </h2>
<p class="First">Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> because of independent effects on hemostasis.</p>
<p>However, at high concentrations <span class="Italics">in vitr</span>o, clopidogrel inhibits CYP2C9.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics Underline">Pregnancy Category B</span></p>
<p>Reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m<span class="Sup">2</span> basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of a human response, Plavix should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk.  It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric populations have not been established.</p>
<p>A randomized, placebo-controlled trial (CLARINET) did not demonstrate a clinical benefit of clopidogrel in neonates and infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt. Possible factors contributing to this outcome were the dose of clopidogrel, the concomitant administration of aspirin and the late initiation of therapy following shunt palliation. It cannot be ruled out that a trial with a different design would demonstrate a clinical benefit in this patient population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with Plavix were 65 years of age and older, and 15% were 75 years and older.  In COMMIT, approximately 58% of the patients treated with Plavix were 60 years and older, 26% of whom were 70 years and older.</p>
<p>The observed risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events with Plavix plus aspirin versus placebo plus aspirin by age category is provided in Table 1 and Table 2 for the CURE and COMMIT trials, respectively <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. No dosage adjustment is necessary in elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Experience is limited in patients with severe and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Platelet inhibition by Plavix is irreversible and will last for the life of the platelet.  <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> following clopidogrel administration may result in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons.  Symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, difficult breathing, and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> in animals.</p>
<p>Based on biological plausibility, platelet transfusion may restore clotting ability.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y<span class="Sub">12</span> ADP platelet receptors. Chemically it is methyl (+)-(<span class="Italics">S</span>)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4<span class="Italics">H</span>)-acetate sulfate (1:1).  The empirical formula of clopidogrel bisulfate is C<span class="Sub">16</span>H<span class="Sub">16</span>ClNO<span class="Sub">2</span>S•H<span class="Sub">2</span>SO<span class="Sub">4</span> and its molecular weight is 419.9.</p>
<p>The structural formula is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-01.jpg"></div>
<p>Clopidogrel bisulfate is a white to off-white powder.  It is practically insoluble in water at neutral pH but freely soluble at pH 1.  It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether.  It has a specific optical rotation of about +56°.</p>
<p>Plavix for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.</p>
<p>Each tablet contains hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose and polyethylene glycol 6000 as inactive ingredients.  The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide and triacetin.  The tablets are polished with Carnauba wax.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y<span class="Sub">12</span> class of ADP receptors on platelets.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y<span class="Sub">12</span> receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.  This action is irreversible.  Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days).  Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.</p>
<p>Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix. Repeated doses of 75 mg Plavix per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg Plavix per day was between 40% and 60%. Platelet aggregation and <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> gradually return to baseline values after treatment is discontinued, generally in about 5 days.</p>
<p><span class="Italics Underline">Geriatric Patients</span></p>
<p>Elderly (≥75 years) and young healthy subjects had similar effects on platelet aggregation. </p>
<p><span class="Italics Underline">Renally-Impaired Patients</span></p>
<p>After repeated doses of 75 mg Plavix per day, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance from 5 to 15 mL/min) and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation. </p>
<p><span class="Italics Underline">Hepatically-Impaired Patients</span></p>
<p>After repeated doses of 75 mg Plavix per day for 10 days in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. </p>
<p><span class="Italics Underline">Gender</span></p>
<p>In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites. </p>
<p><span class="Italics Underline">Absorption</span></p>
<p>After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.</p>
<p><span class="Italics">Effect of Food</span></p>
<p>Plavix can be administered with or without food. In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%. The active metabolite AUC<span class="Sub">0–24</span> was unchanged in the presence of food, while there was a 57% decrease in active metabolite Cmax. Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast. </p>
<p><span class="Italics Underline">Metabolism</span></p>
<p>Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes. Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite. Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. This metabolic pathway is mediated by CYP2C19, CYP3A, CYP2B6 and CYP1A2. The active thiol metabolite binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation for the lifespan of the platelet.</p>
<p>The Cmax of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose. Cmax occurs approximately 30 to 60 minutes after dosing. In the 75 to 300 mg dose range, the pharmacokinetics of the active metabolite deviates from dose proportionality: increasing the dose by a factor of four results in 2.0- and 2.7-fold increases in Cmax and AUC, respectively.</p>
<p><span class="Italics Underline">Elimination</span></p>
<p>Following an oral dose of <span class="Sup">14</span>C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing. After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.  The half-life of the active metabolite is about 30 minutes. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.5"></a><a name="section-11.4"></a><p></p>
<h2>12.5   Pharmacogenomics</h2>
<p class="First">CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by <span class="Italics">ex vivo</span> platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.</p>
<p>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient's CYP2C19 genotype. </p>
<p>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days.  Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see <a href="#Table4">Table 4</a>). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</p>
<a name="Table4"></a><table width="85%">
<caption><span>Table 4: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="left">Dose</th>
<th align="center">Ultrarapid <br>(n=10)</th>
<th align="center">Extensive <br>(n=10)</th>
<th align="center">Intermediate <br>(n=10)</th>
<th class="Rrule" align="center">Poor <br>(n=10)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">Values are mean (SD)</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Inhibition of platelet aggregation with 5mcM ADP; larger value indicates greater platelet inhibition</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Vasodilator-stimulated phosphoprotein – platelet reactivity index; smaller value indicates greater platelet inhibition</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Cmax (ng/mL)</td>
<td align="left">300 mg (24 h)</td>
<td align="center">24 (10)</td>
<td align="center">32 (21)</td>
<td align="center">23 (11)</td>
<td class="Rrule" align="center">11 (4)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">600 mg (24 h)</td>
<td align="center">36 (13)</td>
<td align="center">44 (27)</td>
<td align="center">39 (23)</td>
<td class="Rrule" align="center">17 (6)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">75 mg (Day 5)</td>
<td align="center">12 (6)</td>
<td align="center">13 (7)</td>
<td align="center">12 (5)</td>
<td class="Rrule" align="center">4 (1)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">150 mg (Day 5)</td>
<td align="center">16 (9)</td>
<td align="center">19 (5)</td>
<td align="center">18 (7)</td>
<td class="Rrule" align="center">7 (2)</td>
</tr>
<tr>
<td class="Lrule" align="left">IPA (%)<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
<td align="left">300 mg (24 h)</td>
<td align="center">40 (21)</td>
<td align="center">39 (28)</td>
<td align="center">37 (21)</td>
<td class="Rrule" align="center">24 (26)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">600 mg (24 h)</td>
<td align="center">51 (28)</td>
<td align="center">49 (23)</td>
<td align="center">56 (22)</td>
<td class="Rrule" align="center">32 (25)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">75 mg (Day 5)</td>
<td align="center">56 (13)</td>
<td align="center">58 (19)</td>
<td align="center">60 (18)</td>
<td class="Rrule" align="center">37 (23)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">150 mg (Day 5)</td>
<td align="center">68 (18)</td>
<td align="center">73 (9)</td>
<td align="center">74 (14)</td>
<td class="Rrule" align="center">61 (14)</td>
</tr>
<tr>
<td class="Lrule" align="left">VASP-PRI (%) <a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>
</td>
<td align="left">300 mg (24 h)</td>
<td align="center">73 (12)</td>
<td align="center">68 (16)</td>
<td align="center">78 (12)</td>
<td class="Rrule" align="center">91 (12)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">600 mg (24 h)</td>
<td align="center">51 (20)</td>
<td align="center">48 (20)</td>
<td align="center">56 (26)</td>
<td class="Rrule" align="center">85 (14)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td align="left">75 mg (Day 5)</td>
<td align="center">40 (9)</td>
<td align="center">39 (14)</td>
<td align="center">50 (16)</td>
<td class="Rrule" align="center">83 (13)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"></td>
<td align="left">150 mg (Day 5)</td>
<td align="center">20 (10)</td>
<td align="center">24 (10)</td>
<td align="center">29 (11)</td>
<td class="Rrule" align="center">61 (18)</td>
</tr>
</tbody>
</table>
<p>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.</p>
<p>The relationship between CYP2C19 genotype and Plavix treatment outcome was evaluated in retrospective analyses of Plavix-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) or stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There was no evidence of tumorigenicity when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats at dosages up to 77 mg/kg per day, which afforded plasma exposures &gt;25 times that in humans at the recommended daily dose of 75 mg.</p>
<p>Clopidogrel was not genotoxic in four <span class="Italics">in vitro</span> tests (Ames test, DNA-repair test in rat hepatocytes, gene mutation assay in Chinese hamster fibroblasts, and metaphase chromosome analysis of human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and in one <span class="Italics">in vivo</span> test (micronucleus test by oral route in mice).</p>
<p>Clopidogrel was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg per day (52 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14   CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1   <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span> </h2>
<p class="First"><span class="Italics Underline">CURE</span></p>
<p>The CURE study included 12,562 patients with ACS without ST-elevation (UA or NSTEMI) and presenting within 24 hours of onset of the most recent episode of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or symptoms consistent with <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.  Patients were required to have either ECG changes compatible with new <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> (without ST-elevation) or elevated cardiac enzymes or <span class="product-label-link" type="condition" conceptid="4010039" conceptname="Troponin I">troponin I</span> or T to at least twice the upper limit of normal.  The patient population was largely Caucasian (82%) and included 38% women, and 52% patients ≥65 years of age.</p>
<p>Patients were randomized to receive Plavix (300-mg loading dose followed by 75 mg once daily) or placebo, and were treated for up to one year.  Patients also received aspirin (75–325 mg once daily) and other standard therapies such as heparin.  The use of GPIIb/IIIa inhibitors was not permitted for three days prior to randomization.</p>
<p>The number of patients experiencing the primary outcome (CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) was 582 (9.3%) in the Plavix-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%–28%; p &lt; 0.001) for the Plavix-treated group (see <a href="#Table5">Table 5</a>).</p>
<a name="Table5"></a><table width="100%">
<caption><span>Table 5:  Outcome Events in the CURE Primary Analysis</span></caption>
<col align="left" valign="top" width="31%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="23%">
<thead>
<tr class="First">
<th class="Lrule" align="left">Outcome</th>
<th align="center">Plavix<br> (+ aspirin)<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</th>
<th align="center">Placebo<br> (+ aspirin)<a href="#footnote-13" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Relative Risk<br> Reduction (%)<br> (95% CI)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th align="center">(n=6259)</th>
<th align="center">(n=6303)</th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Other standard therapies were used as appropriate.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>The individual components do not represent a breakdown of the primary and co-primary outcomes, but rather the total number of subjects experiencing an event during the course of the study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Primary outcome<br>  (Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>)</td>
<td align="center">582       (9.3%)</td>
<td align="center">719 (11.4%)</td>
<td class="Rrule" align="center">20%<br> (10.3, 27.9)<br> p &lt; 0.001</td>
</tr>
<tr>
<td class="Lrule" align="left">All Individual Outcome Events:<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a>
</td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td align="center">318       (5.1%)</td>
<td align="center">345 (5.5%)</td>
<td class="Rrule" align="center">7%<br> (-7.7, 20.6)</td>
</tr>
<tr>
<td class="Lrule" align="left">  MI</td>
<td align="center">324       (5.2%)</td>
<td align="center">419 (6.6%)</td>
<td class="Rrule" align="center">23%<br> (11.0, 33.4)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">75       (1.2%)</td>
<td align="center">87 (1.4%)</td>
<td class="Rrule" align="center">14%<br> (-17.7, 36.6)</td>
</tr>
</tbody>
</table>
<p>Most of the benefit of Plavix occurred in the first two months, but the difference from placebo was maintained throughout the course of the trial (up to 12 months) (see <a href="#Fig_1">Figure 1</a>).</p>
<a name="Fig_1"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 1:  Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the CURE Study </span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-03.jpg"></td></tr>
</tbody>
</table>
<p>In CURE, the use of Plavix was associated with a lower incidence of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patient populations with different characteristics, as shown in Figure 2.  The benefits associated with Plavix were independent of the use of other acute and long-term cardiovascular therapies, including heparin/LMWH, intravenous glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, lipid-lowering drugs, beta-blockers, and ACE-inhibitors.  The efficacy of Plavix was observed independently of the dose of aspirin (75–325 mg once daily).  The use of oral anticoagulants, non-study anti-platelet drugs, and chronic NSAIDs was not allowed in CURE.</p>
<a name="Fig_2"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 2: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study </span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-04.jpg"></td></tr>
</tbody>
</table>
<p>The use of Plavix in CURE was associated with a decrease in the use of thrombolytic therapy (71 patients [1.1%] in the Plavix group, 126 patients [2.0%] in the placebo group; relative risk reduction of 43%), and GPIIb/IIIa inhibitors (369 patients [5.9%] in the Plavix group, 454 patients [7.2%] in the placebo group, relative risk reduction of 18%).  The use of Plavix in CURE did not affect the number of patients treated with CABG or PCI (with or without stenting), (2253 patients [36.0%] in the Plavix group, 2324 patients [36.9%] in the placebo group; relative risk reduction of 4.0%).</p>
<p><span class="Italics Underline">COMMIT</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>, the safety and efficacy of Plavix were evaluated in the randomized, placebo-controlled, double-blind study, COMMIT. COMMIT included 45,852 patients presenting within 24 hours of the onset of the symptoms of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> with supporting ECG abnormalities (<span class="Italics">i.e.</span>, ST-elevation, ST-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or left bundle-branch block). Patients were randomized to receive Plavix (75 mg once daily) or placebo, in combination with aspirin (162 mg per day), for 28 days or until hospital discharge, whichever came first.</p>
<p>The primary endpoints were <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause and the first occurrence of re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>The patient population included 28% women, 58% age ≥ 60 years (26% age ≥ 70 years), 55% patients who received thrombolytics, 68% who received ACE-inhibitors, and only 3% who underwent PCI.</p>
<p>As shown in Table 6 and Figure 3 and Figure 4 below, Plavix significantly reduced the relative risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause by 7% (p=0.029), and the relative risk of the combination of re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> by 9% (p=0.002).</p>
<a name="table6"></a><table width="100%">
<caption><span>Table 6: Outcome Events in the COMMIT Analysis</span></caption>
<col align="center" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Event</th>
<th class="Rrule" align="center">Plavix<br> (+ aspirin)<br>(N=22961)</th>
<th class="Rrule" align="center">Placebo<br> (+ aspirin)<br>(N=22891)</th>
<th class="Rrule" align="center">Odds ratio<br>(95% CI)</th>
<th class="Rrule" align="center">p-value</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>The difference between the composite endpoint and the sum of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>+non-fatal MI+non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> indicates that 9 patients (2 clopidogrel and 7 placebo) suffered both a non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and a non-fatal MI.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>Non-fatal MI and non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> exclude patients who died (of any cause).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">Composite endpoint: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></span></td>
<td class="Rrule" align="center" valign="bottom">2121 (9.2%)</td>
<td class="Rrule" align="center" valign="bottom">2310 (10.1%)</td>
<td class="Rrule" align="center" valign="bottom">0.91 (0.86, 0.97)</td>
<td class="Rrule" align="center" valign="bottom">0.002</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td class="Rrule" align="center">1726 (7.5%)</td>
<td class="Rrule" align="center">1845 (8.1%)</td>
<td class="Rrule" align="center">0.93 (0.87, 0.99)</td>
<td class="Rrule" align="center">0.029</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Non-fatal MI<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>
</td>
<td class="Rrule" align="center">270 (1.2%)</td>
<td class="Rrule" align="center">330 (1.4%)</td>
<td class="Rrule" align="center">0.81 (0.69, 0.95)</td>
<td class="Rrule" align="center">0.011</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><a href="#footnote-16" class="Sup">†</a>
</td>
<td class="Rrule" align="center">127 (0.6%)</td>
<td class="Rrule" align="center">142 (0.6%)</td>
<td class="Rrule" align="center">0.89 (0.70, 1.13)</td>
<td class="Rrule" align="center">0.33</td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>All treated patients received aspirin.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 3: Cumulative Event Rates for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in the COMMIT Study <a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a></span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-05.jpg"></td></tr>
</tbody>
</table>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>All treated patients received aspirin.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 4: Cumulative Event Rates for the Combined Endpoint Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in the COMMIT Study <a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a></span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-06.jpg"></td></tr>
</tbody>
</table>
<p>The effect of Plavix did not differ significantly in various pre-specified subgroups as shown in Figure 5. The effect was also similar in non-prespecified subgroups including those based on infarct location, Killip class or prior MI history (see <a href="#Fig_6">Figure 6</a>). Such subgroup analyses should be interpreted cautiously.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 5:  Effects of Adding Plavix to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study</span></td></tr>
<tr class="Toprule"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-07.jpg"></td></tr>
<tr class="Botrule Last"><td align="left">* Three similar-sized prognostic index groups were based on absolute risk of primary composite outcome for each patient calculated from baseline prognostic variables (excluding allocated treatments) with a Cox regression model.</td></tr>
</tbody>
</table>
<a name="fig_6"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 6: Effects of Adding Plavix to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-08.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2   Recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, Recent <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, or Established Peripheral Arterial Disease</h2>
<p class="First"><span class="Italics Underline">CAPRIE</span></p>
<p>The CAPRIE trial was a 19,185-patient, 304-center, international, randomized, double-blind, parallel-group study comparing Plavix (75 mg daily) to aspirin (325 mg daily).  The patients randomized had: 1) recent histories of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (within 35 days); 2) recent histories of <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (within 6 months) with at least a week of residual neurological signs; or 3) established peripheral arterial disease.  Patients received randomized treatment for an average of 1.6 years (maximum of 3 years).</p>
<p>The trial's primary outcome was the time to first occurrence of new <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (fatal or not), new <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (fatal or not), or other vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> not easily attributable to nonvascular causes were all classified as vascular.</p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7:  Outcome Events in the CAPRIE Primary Analysis</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"><span class="Underline">Plavix</span></th>
<th align="center"><span class="Underline">aspirin</span></th>
</tr>
<tr class="Last">
<th align="left">Patients </th>
<th align="center">n=9599</th>
<th align="center">n=9586</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span> (fatal or not) </td>
<td align="center">438 (4.6%)</td>
<td align="center">461 (4.8%)</td>
</tr>
<tr>
<td align="left">MI (fatal or not) </td>
<td align="center">275 (2.9%)</td>
<td align="center">333 (3.5%)</td>
</tr>
<tr class="Botrule">
<td align="left">Other vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td align="center">226 (2.4%)</td>
<td align="center">226 (2.4%)</td>
</tr>
<tr class="Botrule Last">
<td align="left">Total </td>
<td align="center">939 (9.8%)</td>
<td align="center">1020 (10.6%)</td>
</tr>
</tbody>
</table>
<p>As shown in Table 7, Plavix was associated with a lower incidence of outcome events, primarily MI.  The overall relative risk reduction (9.8% vs. 10.6%) was 8.7%, p=0.045.  Similar results were obtained when all-cause mortality and all-cause <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> were counted instead of vascular mortality and <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic strokes</span> (risk reduction 6.9%).  In patients who survived an on-study <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the incidence of subsequent events was lower in the Plavix group.</p>
<p>The curves showing the overall event rate are shown in Figure 7.  The event curves separated early and continued to diverge over the 3-year follow-up period.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 7:  Fatal or Non-Fatal Vascular Events in the CAPRIE Study</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=plavix-02.jpg"></td></tr>
</tbody>
</table>
<p>The statistical significance favoring Plavix over aspirin was marginal (p=0.045). However, because aspirin is itself effective in reducing cardiovascular events in patients with recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, the effect of Plavix is substantial.</p>
<p>The CAPRIE trial included a population that was randomized on the basis of 3 entry criteria.  The efficacy of Plavix relative to aspirin was heterogeneous across these randomized subgroups (p=0.043).  It is not clear whether this difference is real or a chance occurrence.  Although the CAPRIE trial was not designed to evaluate the relative benefit of Plavix over aspirin in the individual patient subgroups, the benefit appeared to be strongest in patients who were enrolled because of <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (especially those who also had a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) and weaker in <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> patients.  In patients who were enrolled in the trial on the sole basis of a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, Plavix was not numerically superior to aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Lack of Established Benefit of Plavix plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</h2>
<p class="First"><span class="Italics Underline">CHARISMA</span></p>
<p>The CHARISMA trial was a 15,603 subject, randomized, double-blind, parallel group study comparing Plavix (75 mg daily) to placebo for prevention of ischemic events in patients with vascular disease or multiple risk factors for <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>.  All subjects were treated with aspirin 75–162 mg daily. The mean duration of treatment was 23 months. The study failed to demonstrate a reduction in the occurrence of the primary endpoint, a composite of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.  A total of 534 (6.9%) patients in the Plavix group versus 573 (7.4%) patients in the placebo group experienced a primary outcome event (p=0.22).  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> of all severities was more common in the subjects randomized to Plavix.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See <a href="#S17.6">Medication Guide (17.6)</a>]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-14.1"></a><p></p>
<h2>17.1	Benefits and Risks</h2>
<ul>
<li>Summarize the effectiveness features and potential side effects of Plavix.</li>
<li>Tell patients to take Plavix exactly as prescribed.</li>
<li>Remind patients not to discontinue Plavix without first discussing it with the physician who prescribed Plavix.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-14.2"></a><p></p>
<h2>17.2	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Inform patients that they:</p>
<ul>
<li>will <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and bleed more easily.</li>
<li>will take longer than usual to stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>should report any unanticipated, prolonged, or excessive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or blood in their stool or urine.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-14.3"></a><p></p>
<h2>17.3	Other Signs and Symptoms Requiring Medical Attention</h2>
<ul>
<li>Inform patients that TTP is a rare but serious condition that has been reported with Plavix and other drugs in this class of drugs.</li>
<li>Instruct patients to get prompt medical attention if they experience any of the following symptoms that cannot otherwise be explained: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, extreme skin paleness, purple skin patches, yellowing of the skin or eyes, or neurological changes.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-14.4"></a><p></p>
<h2>17.4	Invasive Procedures</h2>
<p class="First">Instruct patients to:</p>
<ul>
<li>inform physicians and dentists that they are taking Plavix before any invasive procedure is scheduled.</li>
<li>tell the doctor performing the invasive procedure to talk to the prescribing health care professional before stopping Plavix.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-14.5"></a><p></p>
<h2>17.5	Concomitant Medications</h2>
<p class="First">Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take, including prescription or over-the-counter omeprazole, so the physician knows about other treatments that may affect how Plavix works (<span class="Italics">e.g.</span>, warfarin and NSAIDs) <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-14.6"></a><p></p>
<h2>17.6	Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br>Plavix<span class="Sup">®</span> (PLAV-iks)<br>(clopidogrel bisulfate)<br>tablets</span></p>
<p>Read this Medication Guide before you start taking Plavix and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><a name="What-is-the-most"></a><span class="Bold">What is the most important information I should know about Plavix?</span></p>
<ol>
<li>
<span class="Bold">Plavix may not work as well in people who:</span><ul class="Disc">
<li>
<span class="Bold">have certain genetic factors that affect how the body breaks down Plavix.</span> Your doctor may do genetic tests to make sure Plavix is right for you.</li>
<li>
<span class="Bold">take certain medicines, especially omeprazole (Prilosec<span class="Sup">®</span>).</span> Your doctor may change the medicine you take for stomach acid problems while you take Plavix.</li>
</ul>
</li>
<li>
<span class="Bold">Plavix can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which can be serious and can sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> Plavix is a blood thinner medicine that lowers the chance of blood clots forming in your body. While you take Plavix:<ul class="Disc">
<li>you may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and bleed more easily</li>
<li>you are more likely to have <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span></li>
<li>it will take longer for any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop</li>
</ul>
</li>
</ol>
<p>Call your doctor right away if you have any of these signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</p>
<ul>
<li>unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time</li>
<li>blood in your urine (pink, red or brown urine)</li>
<li>red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar)</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> that happen without a known cause or get larger</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots</li>
<li>vomit blood or your vomit looks like coffee grounds</li>
</ul>
<p>Do not stop taking Plavix without talking to the doctor who prescribes it for you. People who are treated with a stent, and stop taking Plavix too soon, have a higher risk of getting a blood clot on the stent, having a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or dying. If you must stop Plavix because of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, your risk of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> may be higher.</p>
<p><span class="Bold">What is Plavix?</span></p>
<p>Plavix is a prescription medicine used to treat people who have any of the following:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> due to heart problems</li>
<li>poor circulation in their legs (peripheral arterial disease)</li>
<li>a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
</ul>
<p>Plavix is used alone or with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or blood clot that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Platelets are blood cells that help your blood clot normally. Plavix helps to prevent platelets from sticking together and forming a clot that can block an artery.</p>
<p>It is not known if Plavix is safe and effective in children.</p>
<p><span class="Bold">Who should not take Plavix?</span></p>
<p>Do not take Plavix if you:</p>
<ul>
<li>currently have a condition that causes <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, such as a <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span></li>
<li>are allergic to clopidogrel or other ingredients in Plavix. See the end of this leaflet for a complete list of ingredients in Plavix.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking Plavix?</span></p>
<p>Before you take Plavix, tell your doctor if you:</p>
<ul>
<li>have a history of bowel (gastrointestinal) or <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>plan to have surgery or a dental procedure. See "<span class="Bold"><a href="#How-should">How should I take Plavix?</a></span>"</li>
<li>are pregnant or plan to become pregnant. It is not known if Plavix will harm your unborn baby</li>
<li>are breastfeeding or plan to breastfeed. It is not known if Plavix passes into your breast milk. You and your doctor should decide if you will take Plavix or breastfeed. You should not do both without talking to your doctor.</li>
</ul>
<p>Tell all of your doctors and your dentist that you are taking Plavix. They should talk to the doctor who prescribed Plavix for you before you have any surgery or invasive procedure.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription, non-prescription medicines, vitamins and herbal supplements.</p>
<p>Plavix may affect the way other medicines work, and other medicines may affect how Plavix works.  See "<span class="Bold"><a href="#What-is-the-most">What is the most important information I should know about Plavix?</a></span>"</p>
<p>Taking Plavix with certain other medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <span class="Bold">Especially tell your doctor if you take</span>:</p>
<ul>
<li>aspirin, especially if you have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Always talk to your doctor about whether you should take aspirin along with Plavix to treat your condition.</li>
<li>Non-steroidal anti-inflammatory drugs (NSAIDs). Ask your doctor or pharmacist for a list of NSAID medicines if you are not sure.</li>
<li>warfarin (Coumadin<span class="Bold"><span class="Sup">®</span></span>, Jantoven<span class="Bold"><span class="Sup">®</span></span>)</li>
</ul>
<p>Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.</p>
<p><a name="How-should"></a><span class="Bold">How should I take Plavix?</span></p>
<ul>
<li>Take Plavix exactly as your doctor tells you.</li>
<li>Do not change your dose or stop taking Plavix without talking to your doctor first. Stopping Plavix may increase your risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</li>
<li>Take Plavix with aspirin as instructed by your doctor.</li>
<li>You can take Plavix with or without food.</li>
<li>If you miss a dose, take Plavix as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Plavix at the same time unless your doctor tells you to.</li>
<li>If you take too much Plavix, call your doctor or go to the nearest emergency room right away.</li>
<li>Talk with your doctor about stopping your Plavix before you have surgery.  Your doctor may tell you to stop taking Plavix at least 5 days before you have surgery to avoid excessive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during surgery.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Plavix?</span></p>
<p><span class="Bold">Plavix can cause serious side effects including:</span></p>
<ul>
<li>See <span class="Bold">"<a href="#What-is-the-most">What is the most important information I should know about Plavix?</a>"</span>
</li>
<li>
<span class="Bold">A blood clotting problem called <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span> (TTP).</span> TTP can happen with Plavix, sometimes after a short time (less than 2 weeks). TTP is a blood clotting problem where blood clots form in blood vessels; and can happen anywhere in the body. TTP needs to be treated in a hospital right away, because it may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Get medical help right away if you have any of these symptoms and they can not be explained by another medical condition:<ul class="Disc">
<li>purplish spots (called <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>) on the skin or in the mouth (mucous membranes) due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> under the skin</li>
<li>your skin or the whites of your eyes are yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>you feel tired or weak</li>
<li>your skin looks very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>fast heart rate or feeling <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>speech changes</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></li>
<li>low amount of urine, or urine that is pink or has blood in it</li>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>vision changes</li>
</ul>
</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Plavix. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Plavix?</span></p>
<ul><li>Store Plavix at 59°F to 86°F (15°C to 30°C).</li></ul>
<p><span class="Bold">Keep Plavix and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about Plavix</span></p>
<p>Medicines are sometimes used for purposes other than those listed in a Medication Guide. Do not take Plavix for a condition for which it was not prescribed. Do not give Plavix to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Plavix. If you would like more information, talk to your doctor. Ask your doctor or pharmacist for information about Plavix that was written for healthcare professionals.</p>
<p>For more information, go to www.sanofi-aventis.us or www.bms.com or call 1-800-321-1335.</p>
<p><span class="Bold">What are the ingredients in Plavix?</span></p>
<p><span class="Bold">Active ingredient:</span> clopidogrel bisulfate</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p>Tablet: hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose, polyethylene glycol 6000</p>
<p>Film coating: ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide, triacetin, Carnauba wax</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>Plavix 75mg Tablet</h1>
<div class="Figure"><img alt="Image File" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10360cf0-1671-3cbe-cd7c-2c8e8753bd1b&amp;name=label1datamaxfda591.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLAVIX 		
					</strong><br><span class="contentTableReg">clopidogrel bisulfate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63629-1598(NDC:63653-1171)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOPIDOGREL BISULFATE</strong> (CLOPIDOGREL) </td>
<td class="formItem">CLOPIDOGREL</td>
<td class="formItem">75 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">75;1171</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63629-1598-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63629-1598-2</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63629-1598-3</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:63629-1598-4</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020839</td>
<td class="formItem">01/01/1900</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bryant Ranch Prepack
							(171714327)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Bryant Ranch Prepack (171714327)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industrie</td>
<td class="formItem"></td>
<td class="formItem">763683216</td>
<td class="formItem">MANUFACTURE(63629-1598)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bryant Ranch Prepack</td>
<td class="formItem"></td>
<td class="formItem">171714327</td>
<td class="formItem">REPACK(63629-1598), RELABEL(63629-1598)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>266e9384-4b12-453a-ba0a-65bebf9ea245</div>
<div>Set id: 10360cf0-1671-3cbe-cd7c-2c8e8753bd1b</div>
<div>Version: 3</div>
<div>Effective Time: 20121012</div>
</div>
</div> <div class="DistributorName">Bryant Ranch Prepack</div></p>
</body></html>
